BNET noted yesterday that GSK (formerly SmithKline Beecham in the U.K.) maintained the program to create ghostwritten medical journal articles about its antidepressant, Paxil.
A look inside the program brochure reveals that Paxil Product Management at GSK expected its drug sales reps to manage doctors as they engaged with CASSPER, even those physicians who are clearly unfamiliar with existing published data on the drug.
The document (cover pictured) shows that the intent of CASSPER was to flood the market with ghostwritten information. It states:
Paxil Product Management has budgeted for 50 articles for 2000.A GSK rep told the AP:
The program was not heavily used and was discontinued a number of years ago.This section indicates what was available in the program:
The document utilizes a number of hypothetical scenarios in which reps might tempt a doctor to get with the CASSPER program. In one, a doctor mentions that he's had some success with patients using Paxil:
Mention that SB is currently testing a program to encourage physicians to publish their experiences with PAXIL. Acknowledge the demands on the physician's time and explain that SB has contracted with an editorial staff to assist your physicians with any or all aspects of having their clinicial experiences using Paxil published."Scenario Two" indicates that a doctor may have done zero research prior to being pulled into CASSPER:
A physician asks whether there are any published data to support Paxil in specific indications or patient populations.GSK used Complete Healthcare Communications to do the writing and editing:
... provide the proper approved references or refer the physician to the Product Information department.
mention that SB is always interested in expanding the database of published studies on Paxil.
Step 1: Prepare first draft. Working with the first draft of the manuscript, the editotrial staff at CHC ensures proper styling and creates figures and tables ... before the manuscript is sent to the author for review.Download the CASSPER brochure here.
- "CASSPER" Was GSK's Friendly Ghostwriting Program on Paxil
- Allergan Gets on the GSK Merry-Go-Round for a Second Time
- Amgen, GSK Lobby on Healthcare as Execs Enjoy Luxury Benefits
- GSK Q2: Generics Wreak Havoc; Cost Reductions From Layoffs Spent on Advertising
- Docs Say Merck Placed Their Names on Ghostwritten Vioxx Articles
- Elsevier Accused Again in Ghostwriting Scandal - This Time in Wyeth Prempro/Premarin Cases
- Wyeth's Troubles: Ghostwriting to Be Revealed; Centrum Sales Weak
- AstraZeneca's "Smoke and Mirrors" Man Has New Job in Medical Writing
- AZ Seroquel Trial: Was It "Ghostwriting" or "Professional" Writing?